ARCUTIS BIOTHERAPEUTICS INC

NASDAQ: ARQT (Arcutis Biotherapeutics, Inc.)

最近更新时间: 13 Oct, 11:14PM

20.72

0.67 (3.34%)

前收盘价格 20.05
收盘价格 20.23
成交量 1,991,899
平均成交量 (3个月) 1,781,218
市值 2,484,433,152
预期市盈率 (P/E Forward) 263.16
价格/销量 (P/S) 10.13
股市价格/股市净资产 (P/B) 18.33
52周波幅
8.03 (-61%) — 21.56 (4%)
利润日期 28 Oct 2025
营业毛利率 -60.95%
营业利益率 (TTM) -37.25%
稀释每股收益 (EPS TTM) -1.04
季度收入增长率 (YOY) 32.80%
总债务/股东权益 (D/E MRQ) 77.67%
流动比率 (MRQ) 3.55
营业现金流 (OCF TTM) -110.94 M
杠杆自由现金流 (LFCF TTM) -66.54 M
资产报酬率 (ROA TTM) -18.43%
股东权益报酬率 (ROE TTM) -70.57%

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 混合的
Biotechnology (全球的) 混合的 混合的
股票 Arcutis Biotherapeutics, Inc. 看涨 看涨

AIStockmoo 评分

1.3
分析师共识 3.0
内部交易活动 -1.5
价格波动 -1.5
技术平均移动指标 2.5
技术振荡指标 4.0
平均 1.30

相关股票

股票 市值 DY P/E(TTM) P/B
ARQT 2 B - - 18.33
MDGL 9 B - - 14.40
CORT 8 B - 66.69 14.17
NUVL 7 B - - 6.43
VKTX 4 B - - 3.94
ACAD 4 B - 16.23 4.39

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

部门 Healthcare
行业 Biotechnology
投资方式 Small Growth
内部持股比例 1.95%
机构持股比例 108.79%
52周波幅
8.03 (-61%) — 21.56 (4%)
目标价格波幅
29.00 (39%) — 30.00 (44%)
30.00 (Needham, 44.79%) 购买
29.50 (42.38%)
29.00 (Goldman Sachs, 39.96%) 保留
平均值 29.50 (42.38%)
总计 1 购买, 1 保留
平均价格@调整类型 24.94
公司 日期 目标价格 调整类型 价格@调整类型
Goldman Sachs 30 Oct 2025 29.00 (39.96%) 保留 24.92
Needham 28 Oct 2025 30.00 (44.79%) 购买 24.95
07 Aug 2025 22.00 (6.18%) 购买 14.12
名称 平均购买 ($) 平均卖出 ($) 总净额 总净值 ($)
WATANABE TODD - 24.95 -40,000 -998,000
累积净数量 -40,000
累积净值 ($) -998,000
累积平均购买 ($) -
累积平均卖出 ($) 24.95
名称 持有人 日期 类型 数量 价格 价值 ($)
WATANABE TODD 职员 28 Oct 2025 自动卖出 (-) 40,000 24.95 998,000
日期 类型 细节
04 Nov 2025 公告 Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
30 Oct 2025 公告 Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments
30 Oct 2025 公告 Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5
28 Oct 2025 公告 Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results
27 Oct 2025 公告 Arcutis to Present at Upcoming Investor Conferences
24 Oct 2025 公告 Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference
06 Oct 2025 公告 FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
03 Oct 2025 公告 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Sep 2025 公告 Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025
17 Sep 2025 公告 Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
16 Sep 2025 公告 Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award
05 Sep 2025 公告 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Sep 2025 公告 Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5
19 Aug 2025 公告 Arcutis to Present at Upcoming Investor Conferences
08 Aug 2025 公告 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Aug 2025 公告 Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票